v3 Template
C

Crescendo Biologics

Biotechnology / Immuno-oncology
Founded
--
Employees
--
Total Funding
$32.0M
Funding Rounds
1
Last Funding
2023-07-24

About Crescendo Biologics

Crescendo Biologics is a T cell enhancing company focused on developing novel therapeutics in immuno-oncology.

Products & Services

Humabody® VH Platform:A proprietary platform for developing novel T cell enhancing therapeutics.
CB307:A lead clinical candidate in immuno-oncology, with clinical biodistribution data and trials for metastatic castration-resistant prostate cancer (mCRPC).
ZL-1102 (CB001):A topical treatment for psoriasis, currently in a global Phase 2 clinical trial.
CB699:A '2 in 1' immune cell engager, presented as a preclinical candidate at AACR 2024.

Specialties

T cell enhancing therapeutics Immuno-oncology Humabody® technology

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Venture Debt
T: -
FT: Venture Debt
A: 32000000
MR: -
FA: $32 million
FAN: 32000000
D: 2023-07-24
FD: 2023-07-24
7 investors
Venture Debt Latest
2023-07-24
$32.0M
7 investors (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News

Crescendo Biologics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology / Immuno-oncology

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro